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Abstract
Background: Fermented wheat germ extract (FWGE) is a multisubstance composition and, besides others, contains
2-methoxy benzoquinone and 2, 6-dimethoxy benzoquinone which are likely to exert some of its biological effects.
FWGE interferes with anaerobic glycolysis, pentose cycle and ribonucleotide reductase. It has significant
antiproliferative effects and kills tumor cells by the induction of apoptosis via the caspase-poly [ADP-ribose]
polymerase-pathway. FWGE interacts synergistically with a variety of different anticancer drugs and exerted
antimetastatic properties in mouse models. In addition, FWGE modulates immune response by downregulation of
MHC-I complex and the induction of TNF-a and various interleukins. Data in the F-344 rat model provide evidence
for a colon cancer preventing effect of FWGE.
Clinical data from a randomized phase II trial in melanoma patients indicate a significant benefit for patients
treated with dacarbazine in combination with FWGE in terms of progression free survival (PFS) and overall survival
(OS). Similarly, data from studies in colorectal cancer suggested a benefit of FWGE treatment. Besides extension of
OS and PFS, FWGE improved the quality of life in several studies.
Conclusion: In conclusion, available data so far, justify the use of FWGE as a non-prescription medical nutriment
for cancer patients. Further randomized, controlled and large scale clinical studies are mandatory, to further clarify
the value of FWGE as a drug component of future chemotherapy regimens.
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Background
The majority of cancer patients eventually suffers from
tumor cachexia and anorexia during their course of dis-
ease [1]. The pathogenesis of tumor cachexia is still not
fully understood but a multifactorial process including
pro-inflammatory cytokines like IL-6 or TNF-a, neuroen-
docrine hormones, downregulation of IGF-1 and tumor
proteolysis inducing factor is assumed [1,2]. Clinically, the
process of tumor cachexia leads to emaciation, weakness
and fatigue with significant impact on quality of life [1].
On the cellular level, beside others tumor cachexia results
in a suppression of the immunological response and meta-
bolic dysfunction [3]. In addition, recent data have identi-
fied tumor cachexia as an independent predictor of
shorter survival and suggest that cancer patients with sig-
nificant body weight loss have an increased risk of treat-
ment failure [2,3]. These findings support the early
therapeutic intervention like the use of specific nutriments
even before the onset of significant body weight loss, parti-
cularly in cancers well known to induce severe cachexia
like pancreatic cancer [3]. One of the nutrition supple-
ments for cancer patients in current clinical use is fermen-
ted wheat germ extract (FWGE) which is available as an
over the counter dietary supplement in several parts of the
world under the brand name Avemar
®. Like typical for
several other nutrition supplements fermented wheat
germ extract contains hundreds to thousands of different
molecules but based on recent studies with various
extracts from fermented wheat germ it is currently
assumed that the two quinones 2-methoxy benzoquinone
and 2, 6-dimethoxy benzoquinone which are present in
wheat germ as glucosides were likely to be responsible for
some of the biological properties of FWGE [3,4]. The
patented production process of FWGE consists of the
extraction of wheat germs, fermentation by Saccharo-
myces cerevisiae, separation of the fermentation liquid,
drying and granulation. This well defined and fingerprint
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laboratory-standardized compound [3]. The availability of
large quantities of fermented wheat germ extract allowed
an intensified preclinical and clinical research resulting in
the characterization of several mechanisms of action and
it provided evidence for potential versatile clinical activity.
Despite its manifold activities, no meaningful toxicity,
mutagenicity or genotoxicity has been observed [5]. In
addition to its single agent effects, fermented wheat germ
extract appeared not to increase toxicity or to reduce
activity of conventional chemotherapy [6,7]
The objective of this review is to summarize and discuss
the data available on the modes of action and preclinical
and clinical activity of Avemar
® in malignant disease.
Mechanisms of action
Metabolic effect
In comparison to normal tissue, cancer cells display a
hypermetabolic state with in particular upregulated utiliza-
tion of glucose and production of large amounts of lactate
[8]. Glucose serves as substrate for the non-oxidative path-
way of ribose synthesis which is a prerequisite for the
increased nucleic acid production in the rapidly dividing
tumor cells. FWGE inhibits glucose uptake in cancer cells
and interferes with enzymes of the anaerobic glycolysis
and PPP such as transketolase, glucose-6-phosphate dehy-
drogenase, lactate dehydrogenase and hexokinase which
are necessary for the allocation of precursors for RNA and
DNA-synthesis [9-11]. Besides the inhibition of glycolysis
and PPP, FWGE impairs the allocation of precursors
for DNA-synthesis by interference with ribonucleotide
reductase. This protein is the key enzyme for the de novo
synthesis of DNA and it converts ribonucleotides to deox-
yribonucleotide-triphosphates, which are precursors of
DNA-synthesis [12]. The inhibition of these key pathways
of sugar metabolism and DNA-synthesis contributes to
the proliferation inhibiting capacity of FWGE. Ribonucleo-
tide reductase is frequently found to be upregulated in
human cancer cells making it an attractive target for antic-
ancer therapy. Like many other anticancer drugs, e.g. gem-
citabine, fludarabine or clofarabine, FWGE has been
demonstrated to significantly inhibit ribonucleotide reduc-
tase in HT29 human colon cancer and HL-60 human pro-
myelocytic leukemia cell lines [13,14].
Beside its DNA-synthesis interfering effects FWGE
inhibits the activity of cyclooxygenases 1 and 2 with simi-
lar potency. Cyclooxygenases are key enzymes in the
synthesis of prostaglandins from arachidonic acid. Prosta-
glandins regulate inflammatory processes and this might
explain the activity of FWGE in rheumatoid arthritis [15].
Antiproliferative effect
Several research groups, including ours, have studied the
antiproliferative activity of FWGE in human tumor mod-
els in vitro and in vivo [8,10,13,16-22]. In a large in vitro
anticancer drug screen we found FWGE to possess
potential antitumor activity in colon, testis, thyroid,
ovary, NSCLC, breast, gastric, head and neck, hepatoma,
glioblastoma, melanoma, cervix and neuroblastoma
human cancer cell lines. In this set of data, the observed
IC50 ranged from 0.04 to 0.7 mg/ml which is in accor-
dance with reports from other groups [6,23]. In different
cell line or xenograft models, FWGE was found to reduce
tumor growth in a dose dependent manner [9,10,13,
18-20,23,24]. It appears that FWGE kills cells by the
induction of apoptosis via the caspase - PARP-pathway
[9,17].
Of note, beside its single agent activity, FWGE augmen-
ted the activity of tamoxifen in estrogen receptor-positive
breast cancer cells [23,25,26]. In in vitro studies from our
group in colon cancer cell lines, combinations of 5-FU,
oxaliplatin and irinotecan with FWGE exerted additive to
synergistic drug interactions [6]. In in vivo studies, combi-
nations of FWGE and 5-FU or DTIC resulted in synergistic
drug interaction in colon (human HCR-25 cell line) and
melanoma (murine B16 cell line) mouse tumor models
with reduction of tumor size in the colon model and
reduction of incidence of metastasis formation in both
models [19,26]. Szende et al. evaluated the combined treat-
ment of FWGE with dacarbazine, adriablastin, or 5-FU in
MCF-7, HepG2 or Vero cell line, as well as vinorelbine,
cyclophosphamide and doxorubicin in 3LL-HH tumor
bearing mice, and found no significant drug interaction, in
particular no antagonism of the cytostatic drug effect by
FWGE [7]. In addition, combination of FWGE and che-
motherapy did not increase toxicity in mice [7].
Antimetastatic effect
An antimetastatic effect of FWGE alone or in combination
with cytostatic drugs was described by Hidvegi et al. in a
spleen-liver or muscle-lung mouse metastasis model using
3LL-HH, B16 and HCR-25 cell lines [19]. In all three
mouse models, the treatment with FWGE orally at 3 g/kg
daily dosage resulted in a significant reduction of liver or
lung metastasis as compared to control mice [19]. Further-
more, combined treatment of FWGE and either DTIC or
5-FU synergistically decreased the number of metastasis in
the melanoma (B16) and colon cancer (C38) model [19].
In another study reported earlier by Hidvegi et al. FWGE
alone or in combination with vitamin C reduced the inci-
dence of metastasis in 3LL-HH (variant of Lewis lung
carcinoma), B16 (murine melanoma), RWT-M (rat
nephroblastoma) and HCR25 (human colon cancer) in
mouse models [20]. It’s worthy to note that combined
treatment with FWGE and vitamin C exerted an inferior
effect compared to the FWGE alone group in the B16 mel-
anoma model [20].
Immunological effect
Several of the observed preclinical and clinical effects of
FWGE cannot be attributed to its direct antiproliferative
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immune response.
One common way for tumor cells to evade destruc-
tion by the immune system - particularly natural killer
cell activity - is the overexpression of the MHC-I com-
plex. It could be shown, that FWGE significantly
downregulated the cell surface MHC class I proteins
[21]. This process was rather selective for malignant
T- and B-cells since healthy peripheral blood mono-
nuclear cells remained unaffected. The downregulation
of the MHC class I protein was preceded by specific
tyrosine phosphorylation of several intracellular pro-
teins and increase of intracellular calcium concentra-
tions [21].
Tumors follow multiple strategies to escape the
immunological response. Like overexpression of MHC
class I protein, the decreased expression of ICAM-1
protein on the endothelial cells of solid tumor vessels
impairs access of the immune system to the tumor [27].
Reduced ICAM-1 expression impairs leukocyte migra-
tion through the vessel membrane and thereby inhibits
tumor leukocyte infiltration. FWGE was shown to upre-
gulate the expression of ICAM-1 on tumor endothelial
cells and to synergize these effects of tumor necrosis
factor alpha [16]. In the same study, FWGE induced the
production of cytokines. Up to the toxic threshold,
FWGE induced the secretion of TNF-a dose-depen-
dently in myeloid but not in lymphoid cells [16].
Furthermore, Telekes et al. reported an induction of
interleukins such as IL-1a, IL-2, IL-5 and IL-6 [16].
Further hints for an immune stimulatory effect of
FWGE came from skin graft experiments reported by
Hidvegi et al. [19,28]. They used C57B1/10 mice as reci-
pient and the B10 LP sub strain as donor of skin. The
recipient group was subdivided into a group of thymec-
tomized and non-thymectomized mice. After skin trans-
plantation, mice were either treated with FWGE, or not,
and time to skin rejection was measured. As the main
finding, FWGE significantly shortened the time of skin
rejection in the thymectomized mice, indicating an abil-
ity of FWGE to decrease the immune deficiency caused
by thymectomy [19,28].
Prevention of colon cancer
The effect of FWGE on colon carcinogenesis induced by
azoxymethane was studied in F-344 rats. Treatment of
rats with azoxymethane alone induced colon tumors in
83% of all rats. However, if rats were treated with a
combination of azoxymethane and FWGE, the incidence
of colon tumors shrunk to 44.8%. This effect was paral-
leled by a reduction in the number of aberrant crypt
foci in approximately the same magnitude [24]. Despite
these significant results the exact molecular mechanism
of this observation is yet to be established.
Clinical trials
Preclinical data suggested potential activity of FWGE in
colon cancer and melanoma [19]. Consequently, clinical
research was focused on these two entities. A randomized
open label phase II study was performed in stage III mel-
anoma patients comparing adjuvant treatment with
DTIC with a combination of DTIC plus FWGE 8.5 g p.o.
once daily for a period of 12 month [29]. 52 patients
were treated and followed up, for up to seven years.
There was no statistical difference in the baseline para-
meters of the two groups. The primary study end point
was progression-free survival. Overall, results were
encouraging, with an observed PFS for the combination
group of 55.8 months vs. 29.9 for DTIC alone, and OS of
66.2 months for the combination group and 44.7 months
for DTIC alone. These results reached statistical signifi-
cance with a p-value < 0.05. In addition to the improved
survival data, the incidence of adverse events related to
anticancer treatment was lower in the combination arm
[29].
In 1998 two pilot scale phase II studies and one large
scale phase III study were launched in colorectal cancer
[30-32]. All study results were in favor of the combination
group including FWGE treatment. The study performed
by Jakab et al. enrolled 170 patients in a phase III design.
The study was multicentric, and had an open label and
cohort design. Allocation to each treatment arm was made
by patient’s choice. Standard treatment consisted of radical
surgery plus radiotherapy and/or chemotherapy (Mayo
Clinic regimen). Primary end point was progression-free
survival. Due to the allocation design, the two treatment
groups were not balanced, with more patients of advanced
tumor stage (including stage IV) in the FWGE group [32].
PFS and OS were more favourable for the FWGE group
[32]. In a multivariate analysis, tumor stage and treatment
with FWGE were the only significant predictors of survival
[32]. The side effects reported by Jakab et al. were overall
mild and consisted of diarrhea, nausea and vomiting, flatu-
lence, repletion, soft stool and constipation in less than
10% of all patients [32].
Beside the issue of potential prolongation of PFS and
OS by the addition of FWGE to chemotherapy regi-
m e n s ,i t si n f l u e n c eo nt h eq u a l i t yo fl i f eo fc a n c e r
patients was studied amongst others in lung and breast
cancer [15].
In lung cancer, a study was performed with enrollment
of 16 patients receiving either chemotherapy and/or
radiotherapy. FWGE was administered for 8 months and
quality of life was assessed using the EORTC QLQ-C30
questionnaire. After 12 weeks of administration of
FWGE, an improvement of quality of life was reported in
global state of health and fatigue. This improvement
maintained throughout the whole observation period
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breast cancer. 55 patients were enrolled and changes of
quality of life were detected using the EORTC QLQ-C30
questionnaire. The mean observation period was 32
months. Several components of quality of life showed sig-
nificant improvement while on supportive therapy with
FWGE. 3 months after start of treatment improvement
r e a c h e ds i g n i f i c a n c e( p<0 . 0 5 )i np h y s i c a lf u n c t i o n s ,
emotional functions, global state of health, nausea and
vomiting, insomnia and constipation. These improve-
ments remained stable throughout the entire period of
treatment [15].
In a phase III open-label, multicentric study, 60 head
and neck cancer patients (stage III-IV) were divided into
two groups, one treated with standard anti-cancer ther-
apy (SAT) alone, while the other group was treated with
SAT plus FWGE [33]. After 2 months, the Spitzer’s Qual-
ity of Life Index (SQOLI) was significantly improved, and
the levels of the circulating hydroperoxides were signifi-
cantly reduced in the FWGE group [33].
In a preclinical study, FWGE accelerated the regenera-
tion of thrombocytes and reticulocytes in sublethally irra-
diated or cyclophosphamide treated mice [34]. Thus, an
open-label, matched-pair, pilot clinical trial was carried
out to test whether the co-administration of FWGE with
cytotoxic drugs, and the continued administration of
FWGE on its own, can reduce the incidence of treatment-
related febrile neutropenia in children with solid cancers,
compared with the same treatments without FWGE [35].
During the treatment and the follow-up period, there was
no progression of the malignant disease, whereas at end-
point, the number and frequency of febrile neutropenic
events significantly differed between the two groups: 30
febrile neutropenic episodes (24.8%) in the FWGE plus
cytotoxic drugs group versus 46 (43.4%) in the cytotoxic
drugs group (Wilcoxon signed rank test, p < 0.05). The
authors concluded that FWGE may therefore be recom-
mended to reduce the incidence of treatment-related
febrile neutropenia in children with solid cancers [35].
Discussion
Nutritional supplements are being used by a significant
amount of cancer patients to augment their conven-
tional cancer therapy or to improve cancer or therapy-
related symptoms. Some of these nutraceuticals are
approved as dietary food for special medical purposes
for cancer patients. To this group of nutrition supple-
ments belongs the FWGE (Avemar
®).
Preclinical in vitro and in vivo data suggested antiproli-
ferative, antimetastatic and immunological effects of
FWGE [6,13,15,19,21]. In addition, the interference of
FWGE with several metabolic pathways has been well
described [9,10,13,15]. The battery of preclinical data
prompted the performance of some clinical studies, such
as in melanoma and colorectal cancer. Taken together,
these studies suggested that FWGE has the potential to
improve response to chemotherapy and thereby to
extend the PFS and OS of cancer patients even in
advanced stages [29-32]. These interesting set of preclini-
cal and clinical data raise the question of the status of
FWGE: nutritional supplement or anticancer drug?
Looking at the summarized data on the preclinical and
clinical activity profile of FWGE, it seems to be a promis-
ing candidate for further clinical evaluation in the treat-
ment of cancer patients. The interference with the
hypermetabolic state of cancer cells resulting in inhibition
of the necessary pathways to produce the precursors of
DNA-synthesis makes the substance somewhat selective
for malignant cells. This notion is supported by data from
Comin-Anduix et al. who reported an about 50 fold higher
IC50 for FWGE in peripheral blood lymphocytes as com-
pared to Jurkat cells [9]. This relatively broad therapeutic
window is also corroborated by the lack of significant side
effects of FWGE in the in vivo studies and in clinical trials
[19,29,32]. From the clinical and preclinical data, it is sug-
gested that FWGE has single agent activity and appears to
modulate (synergize) the effect of commonly used cyto-
static and other anticancer drugs [6,18,19,21,23,29,32].
The inhibition or lack of G6PDH sensitizes cells to radia-
tion-induced apoptosis [36,37]. Thus, a combination of
FWGE, a potent inhibitor of several enzymes of the PPP
including G6PDH, with radiotherapy appears to be worth
testing. An additional target of FWGE involved in DNA-
synthesis is ribonucleotide reductase, which is upregulated
in several cancers and therefore is considered an impor-
tant target in cancer chemotherapy [14]. Clinically active
drugs like fludarabine or cytarabine and gemcitabine exert
at least, in part, their cytotoxic activity by inhibiting ribo-
nucleotide reductase [14].
FWGE is a multisubstance composition as reflected by
its specific HPLC fingerprint spectra and the exact chemi-
cal composition is yet unknown. Two major components
are the quinones 2-methoxy benzoquinone and 2, 6-
dimethoxy benzoquinone. These two components are con-
sidered to be mainly involved in the antiproliferative and
metabolic activity of FWGE. However, it’ss u g g e s t e db y
data from Hidvegi et al. using a skin graft model that com-
ponents other than the two benzoquinones are responsible
for the immune stimulatory activity of FWGE [28]. On the
other hand, Fajka-Boja et al. demonstrated that FWGE
downregulated MHC-I in malignant B and T cell lines by
a mechanism which is yet not clear in detail. Likely, the
quinone fraction of FWGE is at least, in part, involved in
this phenomenon since comparative studies in Jurkat cells
lead to a 70% decrease of MHC-I when treated with qui-
nones alone, and 90% when treated with the complete
extract [21]. Based on these observations, it’s tempting to
speculate that the skin graft rejection observed by Hidvegi
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lating effects of FWGE like induction of TNF-a, IL-2 and
IL-4 or INF-g [16,38]. In addition, downregulation of
MHC-I protein expression was accompanied by increase
of intracellular calcium concentration and tyrosine phos-
phorylation of some yet unidentified proteins [21]. Overall,
it appears that FWGE exerts its cytotoxic and antimeta-
static effects by a combination of direct cytotoxicity and
immune modulation.
In clinical use, FWGE is very well tolerated at the
recommended dose and posseses a broad therapeutic
window [26]. Besides its antitumoral activity, FWGE
seems to exert additional effects leading to improvement
of quality of life [15]. This might be in part explained by
the metabolic changes in cancer patients induced by
FWGE. Its interference with the PPP switching from
nonoxidative to oxidative reaction leads to decreased
nucleic acid synthesis from glucose to direct glucose oxi-
dation and lipid synthesis. This in turn may result in
weight gain of the patient and improvement of body
shape [15,39]. It is interesting to note, that FWGE has a
similar metabolic effect and targets components of the
PPP like the well known targeted drug imatinib (Glivec
®)
[40].
The clinical properties of FWGE in cancer patients
were observed in a limited number of small and large-
scale studies in different kind of cancers. However,
except the study conducted by Demidov et al., all other
studies were not randomized and do not meet the stan-
dards of clinical trials for drug registration. Thus, the
potential anticancer drug effect of FWGE cannot be
considered as clinically proven. Further well-conducted,
randomized and large-scale trials are mandatory to
prove the supposed effects of FWGE.
In conclusion, available data suggest that FWGE has an
interesting preclinical and clinical activity profile with no
toxicity. It appears to exert its effects by a battery of
diverse mechanisms, likely because of its multi-substance
composition. The use of FWGE as a non-prescription
medical nutriment for cancer patients seems maintainable
and combined use with chemotherapy appears feasible.
However, current data do not justify the use of FWGE as
an anticancer drug. Further randomized, well controlled
and large scale clinical studies meeting the demands of
clinical trials for drug registration are mandatory and war-
ranted to further clarify the potential value of FWGE as a
drug component of future chemotherapy regimens.
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